Cargando…

Methods of Determining Irritable Bowel Syndrome and Efficiency of Probiotics in Treatment: A Review

BACKGROUND: Irritable bowel syndrome (IBS) is a prevalent lifestyle-associated ailment linked to the gut microbiota that significantly influences patients' quality of life. A notable correlation exists between Blastocystis infections and susceptibility to IBS, with infected individuals exhibiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahlawat, Geetika M., Singh, Prabhat K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665699/
https://www.ncbi.nlm.nih.gov/pubmed/38021264
http://dx.doi.org/10.1016/j.curtheres.2023.100721
_version_ 1785138883281813504
author Ahlawat, Geetika M.
Singh, Prabhat K.
author_facet Ahlawat, Geetika M.
Singh, Prabhat K.
author_sort Ahlawat, Geetika M.
collection PubMed
description BACKGROUND: Irritable bowel syndrome (IBS) is a prevalent lifestyle-associated ailment linked to the gut microbiota that significantly influences patients' quality of life. A notable correlation exists between Blastocystis infections and susceptibility to IBS, with infected individuals exhibiting an increased likelihood of developing the condition. Despite promising results from using probiotics to modulate the gut microbiota and manage IBS, the precise mechanisms and potential risks remain unclear. OBJECTIVE: This review aims to explore the therapeutic potential of probiotics, particularly Saccharomyces boulardii, in the management of IBS, highlighting the role of the gut microbiota and the gut–brain axis in IBS pathophysiology. METHODS: A comprehensive literature survey was conducted to examine the association between gut microbiota and IBS, the role of probiotics in managing IBS, the mechanisms of their action, and the potential risks associated with their long-term use. Additionally, this study addresses the influence of Blastocystis infections on IBS susceptibility and evaluates various ongoing clinical trials investigating probiotic use for IBS. RESULTS: S boulardii, a yeast species with probiotic properties, has demonstrated effectiveness in both the treatment and prophylaxis of IBS. Its administration is associated with a decrease in the proinflammatory cytokine interleukin 8 and an increase in the anti-inflammatory cytokine interleukin 10. Probiotics appear to function by inhibiting the growth of pathogenic microorganisms and regulating neurotransmitter activity, influencing the gut–brain axis. However, selecting appropriate probiotic strains and dosing regimens is crucial because of potential adverse effects, such as infections and allergic reactions. CONCLUSIONS: Probiotics, specifically S boulardii, offer a promising avenue for IBS management by modulating gut microbiota. However, further research is necessary to delineate the precise mechanisms of action, optimal strains, dosing regimens for IBS treatment, and potential risks associated with long-term use. A comprehensive approach incorporating probiotics, a low-FODMAP diet, and cognitive-behavioral therapy may provide effective management of IBS symptoms.
format Online
Article
Text
id pubmed-10665699
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-106656992023-10-18 Methods of Determining Irritable Bowel Syndrome and Efficiency of Probiotics in Treatment: A Review Ahlawat, Geetika M. Singh, Prabhat K. Curr Ther Res Clin Exp Review Article BACKGROUND: Irritable bowel syndrome (IBS) is a prevalent lifestyle-associated ailment linked to the gut microbiota that significantly influences patients' quality of life. A notable correlation exists between Blastocystis infections and susceptibility to IBS, with infected individuals exhibiting an increased likelihood of developing the condition. Despite promising results from using probiotics to modulate the gut microbiota and manage IBS, the precise mechanisms and potential risks remain unclear. OBJECTIVE: This review aims to explore the therapeutic potential of probiotics, particularly Saccharomyces boulardii, in the management of IBS, highlighting the role of the gut microbiota and the gut–brain axis in IBS pathophysiology. METHODS: A comprehensive literature survey was conducted to examine the association between gut microbiota and IBS, the role of probiotics in managing IBS, the mechanisms of their action, and the potential risks associated with their long-term use. Additionally, this study addresses the influence of Blastocystis infections on IBS susceptibility and evaluates various ongoing clinical trials investigating probiotic use for IBS. RESULTS: S boulardii, a yeast species with probiotic properties, has demonstrated effectiveness in both the treatment and prophylaxis of IBS. Its administration is associated with a decrease in the proinflammatory cytokine interleukin 8 and an increase in the anti-inflammatory cytokine interleukin 10. Probiotics appear to function by inhibiting the growth of pathogenic microorganisms and regulating neurotransmitter activity, influencing the gut–brain axis. However, selecting appropriate probiotic strains and dosing regimens is crucial because of potential adverse effects, such as infections and allergic reactions. CONCLUSIONS: Probiotics, specifically S boulardii, offer a promising avenue for IBS management by modulating gut microbiota. However, further research is necessary to delineate the precise mechanisms of action, optimal strains, dosing regimens for IBS treatment, and potential risks associated with long-term use. A comprehensive approach incorporating probiotics, a low-FODMAP diet, and cognitive-behavioral therapy may provide effective management of IBS symptoms. Elsevier 2023-10-18 /pmc/articles/PMC10665699/ /pubmed/38021264 http://dx.doi.org/10.1016/j.curtheres.2023.100721 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review Article
Ahlawat, Geetika M.
Singh, Prabhat K.
Methods of Determining Irritable Bowel Syndrome and Efficiency of Probiotics in Treatment: A Review
title Methods of Determining Irritable Bowel Syndrome and Efficiency of Probiotics in Treatment: A Review
title_full Methods of Determining Irritable Bowel Syndrome and Efficiency of Probiotics in Treatment: A Review
title_fullStr Methods of Determining Irritable Bowel Syndrome and Efficiency of Probiotics in Treatment: A Review
title_full_unstemmed Methods of Determining Irritable Bowel Syndrome and Efficiency of Probiotics in Treatment: A Review
title_short Methods of Determining Irritable Bowel Syndrome and Efficiency of Probiotics in Treatment: A Review
title_sort methods of determining irritable bowel syndrome and efficiency of probiotics in treatment: a review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665699/
https://www.ncbi.nlm.nih.gov/pubmed/38021264
http://dx.doi.org/10.1016/j.curtheres.2023.100721
work_keys_str_mv AT ahlawatgeetikam methodsofdeterminingirritablebowelsyndromeandefficiencyofprobioticsintreatmentareview
AT singhprabhatk methodsofdeterminingirritablebowelsyndromeandefficiencyofprobioticsintreatmentareview